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Material and Methods: Cell proliferation analysis was 
performed on human fibrosarcoma, liposarcoma, 
leiomyosarcoma and rhabdomyosarcoma cell lines with 
increasing doses of olaparib (0.25; 0.5; 1; 2; 4 μM) 3 h after 
cells seeding. The numbers of cells were assessed after 5 
days and results normalized to the untreated control. For 
clonogenic assays, fibrosarcoma, liposarcoma, 
leiomyosarcoma and rhabdomyosarcoma cells were irradiated 
with 2, 4 or 6 Gy, with or without olaparib (1 µM) iniparib (10 
µM) or veliparib (5μM) pre-treatment. The plating efficiency 
of the combined treatments were normalized to PARPi-
treated cells. The linear-quadratic survival expression was 
fitted to the data by nonlinear regression. The 
radiosensitization enhancement ratio for the PARPi at 50% 
survival (ER50) was as follows: ER50 = Dose at 50% survival 
without PARPi/Dose at 50% survival with PARPi. The impact 
of PARP inhibition on γ-H2Ax foci formation was evaluated in 
rhabdomyosarcoma cells treated with olaparib 1 μM after 48 
h, and irradiated at 4 Gy. Cells were probed with primary 
antibody to γ-H2AX. 
 
Results: Continuous treatment with olaparib for 5 days 
resulted in a dose-dependent inhibition of proliferation in all 
the STS cell lines. Significant radiosensitization was observed 
in all human STS cell lines using PARPi, with an ER50 ranging 
from 1.2 to 3.41. Rhabdomyosarcoma showed the greatest 
increase in radiosensitivity, with an ER50 of 3.41 with 
veliparib. Fibrosarcoma showed an ER50 of 2.29 with olaparib 
and 2.21 with veliparib. Leiomyosarcoma and liposarcoma 
showed similar radiation responses after PARP inhibition, 
with the higher radiosensitization in presence of veliparib 
(ER50 1.62 and 1.46, respectively). The combination of 
olaparib and radiation in rhabdomyosarcoma cells resulted in 
an increased number of γH2AX foci as compared to control 
and irradiation alone. 
 
Conclusion: We demonstrated that PARPi are potent 
radiosensitizers on human STS in vitro models. The different 
PARPi radiosensitizing effects observed in various cell lines 
may be explained by the presence of different genomic 
aberrations in DNA repair machinery in specific STS subtypes. 
These preliminary data encourage to further study 
association of PARPi with IR as a promising treatment for STS. 
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Purpose or Objective: Glioblastoma (GBM) is the most 
common primary brain tumor in adults. Despite intense 
treatment, including surgery and radiochemotherapy, 
prognosis is dismal with a median overall survival time of only 
15 months. The vascular endothelial growth factor-A (VEGF-
A) has been identified as one of the key regulators of 
neoangiogenesis in these highly vascularized tumors. 
Therefore, disruption of the VEGF-A signaling cascade by 
neutralizing VEGF-A and preventing ligation of its receptors 
appeared to be a promising approach for targeting 
neoangiogenesis. However, in recent phase III trials 
application of the VEGF-A blocking antibody bevacizumab in 
combination with radiochemotherapy failed to prolong 
overall survival in newly diagnosed GBM despite increasing 
progression-free survival and improving performance status. 
The aim of our study was to analyze the treatment effects of 
radiotherapy in combination with bevacizumab in a clinically 
relevant setting. Therefore, we established an orthotopic, 
syngeneic mouse glioblastoma model and subjected it to 
fractionated radiotherapy in combination with the 
bevacizumab mouse analogue G6-31. 
Material and Methods: GL261 mouse GBM cells were 
stereotactically transplanted into the frontal lobe of C57/BL6 
mice and tumors were allowed to grow for one week. 
Radiation therapy was performed with a Small Animal 
Radiation Research Platform (SARRP, Xstrahl) which 
incorporates contrast agent-CT (CA-CT)-based imaging 
followed by high precision radiation delivery. Fractionated 
irradiation with daily doses of 2 Gy up to a cumulative dose 
of 20 Gy was administered with or without accompanying 
VEGF-A blockade by the mouse bevacizumab analogue G6-31. 
Overall survival and tumor size were monitored, histological 
analyses, and transcriptomic profiling of tumor and normal 
tissue are currently being performed. 
 
Results: Stereotactic implantation of GBM was successfully 
accomplished, fractionated irradiation was implemented by 
CA-CT-based image guidance, and tumor growth was 
successfully monitored by serial CA-CT scans. The single 
agent treatments led to a significant delay in tumor growth 
and prolongation of survival as compared to the sham-treated 
controls. Importantly, the strongest therapeutic effects were 
observed with the combined treatment. Histological details, 
including vessel density and structure, as well as markers of 
cell death induction, and transcriptomic profiling of tumor 
and normal tissue are currently under investigation. 
 
Conclusion: This pilot study shows that syngeneic, orthotopic 
glioblastoma transplants combined with stereotactically 
delivered radiotherapy are feasible and clinically relevant in 
vivo models for evaluating the therapeutic efficacy of 
multimodal treatment approaches based on fractionated 
irradiation. 
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Purpose or Objective: Injected gold nano particles(GNPs) to 
a body for dose enhancement are known to form cluster 
morphology. We investigated the dependence of dose 
enhancement on the morphology characteristic with an 
approximated morphology model by using Monte Carlo 
simulations. 
 
Material and Methods: For MC simulation, TOPAS v.b-12 was 
used. GNPs of 50 and 100 nm diameter were tested. GNP 
cluster morphology was approximated as a body center cubic 
by placing 8 GNPs at the corner and one at the centered of a 
2 × 2 × 2 μm³, 1 × 1 × 1 μm³, 0.5 × 0.5 × 0.5 μm³, or 0.25 × 
0.25 × 0.25 μm³ (for 100 nm GNP) or 0.18 × 0.18 × 0.18 μm³ 
(for 50 nm GNP) cube located in a 4 × 4 × 4 μm³ water filled 
cube phantom. 4 μm × 4 μm square shaped beams of 
spectrum-energetic 50, 100 kVp photons and 70, 170 MeV 
protons were irradiated to the water filled cube phantom 
with GNPs in it. We computed the distribution of secondary 
electrons as a function of distance from the surface of the 
GNP at the cube center and calculated the ratio (SER) 
together with dose enhancement ratio (DER) for 4 different 
cubes geometries. For scoring particles,10 nm width of 
concentric shell shaped detector was constructed up to 100 
nm from the center point of the cube. 10E8 histories of 
protons and 2 × 10E10 histories of photons were used for 
simulation. All counted values at each detector were summed 
to obtain the total dose and secondary electrons in a sphere 
of 100 nm radius and were normalized to 2 × 2 × 2 μm³ cube 
morphology. 
